Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2010 2
2011 3
2012 1
2013 3
2014 4
2015 3
2016 3
2017 4
2018 5
2019 3
2020 1
2021 4
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
Patel PS, Abraham KJ, Guturi KKN, Halaby MJ, Khan Z, Palomero L, Ho B, Duan S, St-Germain J, Algouneh A, Mateo F, El Ghamrasni S, Barbour H, Barnes DR, Beesley J, Sanchez O, Berman HK, Brown GW, Affar EB, Chenevix-Trench G, Antoniou AC, Arrowsmith CH, Raught B, Pujana MA, Mekhail K, Hakem A, Hakem R. Patel PS, et al. Among authors: berman hk. J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105. J Clin Invest. 2021. PMID: 33529165 Free PMC article.
However, the molecular mechanisms that influence cancer risk and therapeutic benefit or resistance remain only partially understood. ...We demonstrate that RNF168 deficiency resulted in accumulation of R-loops in BRCA1/2-mutant breast and ovarian cancer cells, leadi …
However, the molecular mechanisms that influence cancer risk and therapeutic benefit or resistance remain only partially understood. …
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages.
Kim H, Aliar K, Tharmapalan P, McCloskey CW, Kuttanamkuzhi A, Grünwald BT, Palomero L, Mahendralingam MJ, Waas M, Mer AS, Elliott MJ, Zhang B, Al-Zahrani KN, Langille ER, Parsons M, Narala S, Hofer S, Waterhouse PD, Hakem R, Haibe-Kains B, Kislinger T, Schramek D, Cescon DW, Pujana MA, Berman HK, Khokha R. Kim H, et al. Among authors: berman hk. Cell Rep. 2023 Oct 31;42(10):113256. doi: 10.1016/j.celrep.2023.113256. Epub 2023 Oct 16. Cell Rep. 2023. PMID: 37847590 Free article.
Consequently, basal progenitors were far more sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis) in both mouse and human mammary epithelium. Furthermore, PARPi sensitivity of murine and human breast cancer cell lines as well as patient-derived xenografts correlat …
Consequently, basal progenitors were far more sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis) in both mouse and human mammary e …
All is not lost: learning from 9p21 loss in cancer.
Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL. Spiliopoulou P, et al. Among authors: berman hk. Trends Immunol. 2022 May;43(5):379-390. doi: 10.1016/j.it.2022.03.003. Epub 2022 Apr 1. Trends Immunol. 2022. PMID: 35379580 Free article. Review.
The cancer research community continues to search for additional biomarkers of response and resistance to immune checkpoint treatment (ICT). ...In this opinion, we argue that there may be additional knowledge gained about immune evasion in cancer by analyzing the lo …
The cancer research community continues to search for additional biomarkers of response and resistance to immune checkpoint treatment …
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ. Cindy Yang SY, et al. Among authors: berman hk. Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7. Nat Commun. 2021. PMID: 34446728 Free PMC article. Clinical Trial.
Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer types. Yet, limited data exist to show the relationship between ctDNA dynamics and tumor genome …
Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (IC …
Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention.
Tharmapalan P, Mahendralingam M, Berman HK, Khokha R. Tharmapalan P, et al. Among authors: berman hk. EMBO J. 2019 Jul 15;38(14):e100852. doi: 10.15252/embj.2018100852. Epub 2019 Jun 21. EMBO J. 2019. PMID: 31267556 Free PMC article. Review.
Breast cancer prevention is daunting, yet not an unsurmountable goal. Mammary stem and progenitors have been proposed as the cells-of-origin in breast cancer. Here, we present the concept of limiting these breast cancer precursors as a risk reduction approach …
Breast cancer prevention is daunting, yet not an unsurmountable goal. Mammary stem and progenitors have been proposed as the cells-of …
Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.
Mrkonjic M, Berman HK, Done SJ, Youngson B, Mulligan AM. Mrkonjic M, et al. Among authors: berman hk. J Clin Pathol. 2019 Feb;72(2):120-132. doi: 10.1136/jclinpath-2018-205598. J Clin Pathol. 2019. PMID: 30670564 Review.
Neoadjuvant systemic therapy is becoming more commonly used in patients with earlier stages of breast cancer. To assess tumour response to neoadjuvant chemotherapy, pathological evaluation is the gold standard. ...
Neoadjuvant systemic therapy is becoming more commonly used in patients with earlier stages of breast cancer. To assess tumour respon …
Mammary epithelial cells have lineage-rooted metabolic identities.
Mahendralingam MJ, Kim H, McCloskey CW, Aliar K, Casey AE, Tharmapalan P, Pellacani D, Ignatchenko V, Garcia-Valero M, Palomero L, Sinha A, Cruickshank J, Shetty R, Vellanki RN, Koritzinsky M, Stambolic V, Alam M, Schimmer AD, Berman HK, Eaves CJ, Pujana MA, Kislinger T, Khokha R. Mahendralingam MJ, et al. Among authors: berman hk. Nat Metab. 2021 May;3(5):665-681. doi: 10.1038/s42255-021-00388-6. Epub 2021 May 20. Nat Metab. 2021. PMID: 34031589
Cancer metabolism adapts the metabolic network of its tissue of origin. ...Thus, lineage-rooted metabolic identities of normal mammary cells may underlie breast cancer metabolic heterogeneity and targeting these vulnerabilities could advance breast cancer the
Cancer metabolism adapts the metabolic network of its tissue of origin. ...Thus, lineage-rooted metabolic identities of normal mammar
RANKL/RANK control Brca1 mutation-.
Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM. Sigl V, et al. Among authors: berman h. Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31. Cell Res. 2016. PMID: 27241552 Free PMC article.
Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides environmental triggers and hormones, inherited mutations in the breast cancer 1 (BRCA1) or BRCA2 genes markedly increase the risk for th …
Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides env …
Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids.
Prince E, Cruickshank J, Ba-Alawi W, Hodgson K, Haight J, Tobin C, Wakeman A, Avoulov A, Topolskaia V, Elliott MJ, McGuigan AP, Berman HK, Haibe-Kains B, Cescon DW, Kumacheva E. Prince E, et al. Among authors: berman hk. Nat Commun. 2022 Mar 18;13(1):1466. doi: 10.1038/s41467-022-28788-6. Nat Commun. 2022. PMID: 35304464 Free PMC article.
We propose a nanofibrillar hydrogel (EKGel) for the initiation and growth of breast cancer PDOs. PDOs grown in EKGel have histopathologic features, gene expression, and drug response that are similar to those of their parental tumors and PDOs in BME. ...These results show …
We propose a nanofibrillar hydrogel (EKGel) for the initiation and growth of breast cancer PDOs. PDOs grown in EKGel have histopathol …
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Salawu A, Wang BX, Han M, Geady C, Heirali A, Berman HK, Pfister TD, Hernando-Calvo A, Al-Ezzi EM, Stayner LA, Gupta AA, Ayodele O, Lam B, Hansen AR, Spreafico A, Bedard PL, Butler MO, Avery L, Coburn B, Haibe-Kains B, Siu LL, Abdul Razak AR. Salawu A, et al. Among authors: berman hk. Clin Cancer Res. 2023 Oct 13;29(20):4128-4138. doi: 10.1158/1078-0432.CCR-23-1137. Clin Cancer Res. 2023. PMID: 37566240
43 results